<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581111</url>
  </required_header>
  <id_info>
    <org_study_id>ODRC-001</org_study_id>
    <nct_id>NCT02581111</nct_id>
  </id_info>
  <brief_title>Naloxone for Optimizing Hypoxemia Of Lung Donors</brief_title>
  <acronym>NO-HOLDS</acronym>
  <official_title>Randomized Placebo-controlled Trial of Intravenous Naloxone to Improve Oxygenation in Hypoxemic Lung-Eligible Brain-Dead Organ Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain-dead patients who provide authorization for organ donation will be randomized to
      naloxone or placebo if baseline arterial blood gas (ABG) after initiation of OPO (Organ
      Procurement Organization) management reveals hypoxemia, as defined by the ratio of partial
      pressure of oxygen in arterial blood (PaO2) to fraction of inspired oxygen (FiO2) below 300
      mm Hg, unless they have already been ruled-out for lung recovery. Investigators aim to assess
      whether naloxone improves oxygenation prior to organ recovery more than placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Naloxone has been used by many OPOs for decades to improve the pulmonary status of brain-dead
      organ donors (based on anecdotal evidence and small uncontrolled studies). Its efficacy in
      this population has never been assessed in a controlled clinical trial. The rationale for its
      use appears to be that it blocks the increase in capillary permeability that occurs with
      herniation and brain death (as demonstrated in a single sheep study of herniation).
      Investigators aim to rigorously test this hypothesis in a randomized placebo-controlled trial
      in brain-dead organ donors who have baseline hypoxemia. The primary outcome will be the acute
      change in oxygenation (on first follow-up ABG after naloxone as well as the final ABG prior
      to organ recovery). Investigators will also assess whether treatment results in more lungs
      being recovered and transplanted, after correcting for baseline variables such as age, blood
      group, smoking history, and cause of death. This study will be performed under the auspices
      of the Organ Donation Research Consortium and be carried out by multiple OPOs across the
      country. Naloxone or blinded placebo (identical syringe filled with saline) will be given
      after the baseline ABG shows hypoxemia (PFR - PaO2 divided by FiO2, on positive
      end-expiratory pressure [PEEP] of 5 and usually 100% FiO2). Naloxone and placebo will both be
      co-administered with a neuromuscular blocking agent (e.g. vecuronium, per center protocol) to
      obviate any increase in spinal reflex movements that may be potentiated by naloxone
      treatment. All other protocols for organ donor management should be maintained at each OPO
      and no other study interventions are required. Transplant centers will be informed (through
      DonorNet) that the organ donor being considered for lung recovery has been enrolled in this
      blinded clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">September 25, 2017</completion_date>
  <primary_completion_date type="Actual">September 22, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Oxygenation (P/F Ratio) From Baseline to Final Pre-recovery Arterial Blood Gas (ABG)</measure>
    <time_frame>Baseline and at time of organ recovery, within 72 hours</time_frame>
    <description>Change in ratio of partial pressure of oxygen in arterial blood (PaO2) to fraction of inspired oxygen (FiO2) from final ABG performed before organ recovery compared to baseline ABG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had Lungs Transplanted</measure>
    <time_frame>At time of organ recovery (within 72 hours)</time_frame>
    <description>Whether one or both lungs were transplanted from this organ donor (dichotomized)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Change in Oxygenation (P/F Ratio)</measure>
    <time_frame>Baseline and ABG at 4-6 hours after intervention</time_frame>
    <description>Change in PaO2:FiO2 ratio from ABG at 4-6 hours after randomization compared to baseline prior to randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Brain Death</condition>
  <condition>Organ Donors</condition>
  <condition>Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>Naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naloxone 8-mg IV given once after baseline ABG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Equivalent volume of saline given once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>Naloxone 8-mg IV bolus</description>
    <arm_group_label>Naloxone</arm_group_label>
    <other_name>Narcan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Brain-dead organ donor being managed by OPO (organ procurement organization)

          -  Lungs being considered for recovery and transplant

          -  Baseline ABG (after authorization) with P/F ratio &lt; 300

        Exclusion Criteria:

          -  No authorization for research

          -  Lungs already excluded for transplant (e.g. known chronic obstructive pulmonary
             disease [COPD], human immunodeficiency virus [HIV] infection)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajat Dhar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Donor Alliance</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Organ Procurement Agency</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-America Transplant Services</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifeline of Ohio</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <results_first_submitted>August 20, 2018</results_first_submitted>
  <results_first_submitted_qc>September 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 16, 2018</results_first_posted>
  <last_update_submitted>September 19, 2018</last_update_submitted>
  <last_update_submitted_qc>September 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Raj Dhar</investigator_full_name>
    <investigator_title>Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Death</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 14, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02581111/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 14, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02581111/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naloxone</title>
          <description>Naloxone 8-mg IV given once after baseline ABG
Naloxone: Naloxone 8-mg IV bolus</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Equivalent volume of saline given once
Normal saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naloxone</title>
          <description>Naloxone 8-mg IV given once after baseline ABG
Naloxone: Naloxone 8-mg IV bolus</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Equivalent volume of saline given once
Normal saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="199"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.4" spread="13"/>
                    <measurement group_id="B2" value="36.8" spread="13"/>
                    <measurement group_id="B3" value="37" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Oxygenation (P/F Ratio) From Baseline to Final Pre-recovery Arterial Blood Gas (ABG)</title>
        <description>Change in ratio of partial pressure of oxygen in arterial blood (PaO2) to fraction of inspired oxygen (FiO2) from final ABG performed before organ recovery compared to baseline ABG</description>
        <time_frame>Baseline and at time of organ recovery, within 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naloxone</title>
            <description>Naloxone 8-mg IV given once after baseline ABG
Naloxone: Naloxone 8-mg IV bolus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Equivalent volume of saline given once
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oxygenation (P/F Ratio) From Baseline to Final Pre-recovery Arterial Blood Gas (ABG)</title>
          <description>Change in ratio of partial pressure of oxygen in arterial blood (PaO2) to fraction of inspired oxygen (FiO2) from final ABG performed before organ recovery compared to baseline ABG</description>
          <units>mm Hg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="19" upper_limit="176"/>
                    <measurement group_id="O2" value="80" lower_limit="-13" upper_limit="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had Lungs Transplanted</title>
        <description>Whether one or both lungs were transplanted from this organ donor (dichotomized)</description>
        <time_frame>At time of organ recovery (within 72 hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naloxone</title>
            <description>Naloxone 8-mg IV given once after baseline ABG
Naloxone: Naloxone 8-mg IV bolus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Equivalent volume of saline given once
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Lungs Transplanted</title>
          <description>Whether one or both lungs were transplanted from this organ donor (dichotomized)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Change in Oxygenation (P/F Ratio)</title>
        <description>Change in PaO2:FiO2 ratio from ABG at 4-6 hours after randomization compared to baseline prior to randomization</description>
        <time_frame>Baseline and ABG at 4-6 hours after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naloxone</title>
            <description>Naloxone 8-mg IV given once after baseline ABG
Naloxone: Naloxone 8-mg IV bolus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Equivalent volume of saline given once
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Change in Oxygenation (P/F Ratio)</title>
          <description>Change in PaO2:FiO2 ratio from ABG at 4-6 hours after randomization compared to baseline prior to randomization</description>
          <units>mm Hg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="-9" upper_limit="129"/>
                    <measurement group_id="O2" value="33" lower_limit="-12" upper_limit="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Till organ recovery (maximum of three days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Naloxone</title>
          <description>Naloxone 8-mg IV given once after baseline ABG
Naloxone: Naloxone 8-mg IV bolus</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Equivalent volume of saline given once
Normal saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>10 subjects were enrolled despite baseline PaO2:FiO2 ratio above 300 (i.e. protocol violations)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Rajat Dhar</name_or_title>
      <organization>Washington University in St. Louis School of Medicine</organization>
      <phone>3143622999</phone>
      <email>dharr@neuro.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

